Skip to main content
Premium Trial:

Request an Annual Quote

BGI Coronavirus Molecular Diagnostic Test Garners CE Mark

NEW YORK – BGI said late on Friday that its Real-Time Fluorescent RT-PCR kit for detecting SARS-CoV-2 (also known as 2019-nCoV) has received CE-IVD marking and is now commercially available in markets recognizing the designation.

BGI's kit is a qualitative in vitro nucleic acid amplification assay that detects 2019-mCoV, the cause of COVID-19, using reverse transcriptase PCR from throat swab and bronchoalveolar lavage fluid samples.

The CE-IVD mark follows approval by China's National Medical Products Administration in late January of BGI's PCR kit and BGI subsidiary MGI's full sequencing platform and metagenomic sequencing assay for SARS-CoV-2 detection.

BGI said the PCR assay is already widely used in China for diagnosing suspected cases and determining whether recovered patients should be discharged. The Huo-Yan Laboratory in Wuhan, the emergency test laboratory run by BGI, is designed to handle 10,000 samples daily using the kits daily, the company said.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.